病毒与淋巴瘤 - betway必威登陆网址

国际肿瘤学杂志››2014,Vol. 41››Issue (2): 127-130.doi:10.3760/cma.j.issn.1673-422X.2014.02.015

• 综述 •上一篇下一篇

病毒与淋巴瘤

吴遐, 汪运生, 邓芳

230031 合肥，安徽省肿瘤医院检验科（吴遐、邓芳）；合肥市第二人民医院广德路院区内分泌科（汪运生）

收稿日期:2013-09-24修回日期:2013-12-25出版日期:2014-02-08发布日期:2014-01-26
通讯作者:邓芳，E-mail: 172027511@qq.com E-mail:172027511@qq.com

Virus and malignant lymphoma

Wu Xia, Wang Yunsheng, Deng Fang

Department of Clinical Laboratory, Anhui Provincial Tumor Hospital, Hefei 230031, China

Received:2013-09-24Revised:2013-12-25Online:2014-02-08Published:2014-01-26
Contact:Deng Fang E-mail:172027511@qq.com

摘要/Abstract

摘要：病毒感染是导致机体发生淋巴瘤的主要病因之一。研究发现爱泼斯坦巴尔病毒(EBV)、人免疫缺陷病毒(HIV)、丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)等均是通过不同途径及机制感染机体，导致淋巴瘤的发生发展。对于病毒感染所致淋巴瘤的研究将有利于阐明淋巴瘤发生的分子机制，并对进一步探索有效的治疗方案具有重要意义。

吴遐, 汪运生, 邓芳. 病毒与淋巴瘤[J]. 国际肿瘤学杂志, 2014, 41(2): 127-130.

Wu Xia, Wang Yunsheng, Deng Fang. Virus and malignant lymphoma[J]. Journal of International Oncology, 2014, 41(2): 127-130.

参考文献

［1］ Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and nonHodgkin lymphomas: a review of the epidemiological evidence［J］. J Intern Med, 2008, 264(6): 537-548. ［2］ Wu ZZ, Chow KP, Kuo TC, et al. Latent membrane protein 1 of EpsteinBarr virus sensitizes cancer cells to cisplatin by enhancing NFκB p50 homodimer formation and downregulating NAPA expression［J］. Biochem Pharmacol, 2011, 82(12): 1860-1872. ［3］ Lu J, Murakami M, Verma SC, et al. EpsteinBarr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBVpositive Blymphoma cells through upregulation of survivin［J］. Virology, 2011, 410(1): 64-75. ［4］ Muromoto R, Ikeda O, Okabe K, et al. EpsteinBarr virusderived EBNA2 regulates STAT3 activation［J］. Biochem Biophys Res Commun, 2009, 378(3): 439-443. ［5］ Staudt LM. Ⅱ. Therapy of DLBCL based on genomics［J］. Hematol Oncol, 2013, 1: 26-28. ［6］ Souza EM, Baiocchi OC, Zanichelli MA, et al. Impact of EpsteinBarr virus in the clinical evolution of patients with classical Hodgkin′s lymphoma in Brazil［J］. Hematol Oncol, 2010, 28(3): 137-141. ［7］ Lima RT, Seca H, Soares P, et al. EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide［J］. J Cell Biochem, 2011, 112(1): 200-210. ［8］ Cheng W, Li YM, Yang DJ, et al. Effect of gossypol acetate on proliferation and apoptosis in Raji lymphoblastoid cell line［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2009, 31(5): 527-532. ［9］ Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of EpsteinBarr virusDNA in plasma and peripheral blood mononuclear cells of extranodal NK/Tcell lymphoma, nasal type［J］. Blood, 2011, 118(23): 6018-6022. ［10］ Ian MX, Lan SZ, Cheng ZF, et al. Suppression of EBNA1 expression inhibits growth of EBVpositive NK/T cell lymphoma cells［J］. Cancer Biol Ther, 2008, 7(10): 1602-1606. ［11］ Omar H, Hgglund H, GustafssonJernberg A, et al. Targeted monitoring of patients at high risk of posttransplant lymphoproliferative disease by quantitative EpsteinBarr virus polymerase chain reaction［J］. Transpl Infect Dis, 2009, 11(5): 393-399. ［12］ Peric Z, Cahu X, Chevallier P, et al. Features of EpsteinBarr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation［J］. Leukemia, 2011, 25(6): 932-938. ［13］ Peric Z, Cahu X, Chevallier P, et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation［J］. Bone Marrow Transplant, 2012, 47(2): 251-257. ［14］ Toulza F, Nosaka K, Takiguchi M, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV1associated adult Tcell leukemia［J］. Int J Cancer, 2009, 125(10): 2375-2382. ［15］ Kozako T, Yoshimitsu M, Fujiwara H, et al. PD1/PDL1 expression in human Tcell leukemia virus type 1 carriers and adult Tcell leukemia/lymphoma patients［J］. Leukemia, 2009, 23(2): 375-382. ［16］ Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDSrelated lymphoma［J］. J Clin Oncol, 2010, 28(5): 773-779. ［17］ Wiggill TM, Mantina H, Willem P, et al. Changing pattern of lymphoma subgroups at a tertiary academic complex in a highprevalence HIV setting: a South African perspective［J］. J Acquir Immune Defic Syndr, 2011, 56(5): 460-466. ［18］ Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of nonAIDSdefining cancers in people with HIV infection［J］. J Clin Oncol, 2009, 27(6): 884-890. ［19］ Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early and lateHAART periods: the Swiss HIV Cohort Study［J］. Br J Cancer, 2010, 103(3): 416-422. ［20］ Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors［J］. J Immunol, 2012, 188(1): 497-503. ［21］ Tussiwand R, Rauch M, Flück LA, et al. BAFFR expression correlates with positive selection of immature B cells［J］. Eur J Immunol, 2012, 42(1): 206-216. ［22］ Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferonalpha, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a longterm study［J］. Blood, 2010, 116(3): 343-353. ［23］ Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa2b plus ribavirin for HCVpositive mixed cryoglobulinemia: a multicentre openlabel study［J］. Clin Exp Rheumatol, 2011, 29(6): 933-941. ［24］ HartridgeLambert SK, Stein EM, Markowitz AJ, et al. Hepatitis C and nonHodgkin lymphoma: the clinical perspective［J］. Hepatology, 2012, 55(2): 634-641. ［25］ Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virusassociated mixed cryoglobulinemia contain an expanded anergic CD21low Bcell subset［J］. Blood, 2011, 117(20): 5425-5437. ［26］ Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to nonHodgkin′s lymphoma［J］. Clinl Gastroenterol Hepatol, 2009, 7(8): 900-905. ［27］ Becker N, Fortuny J, Alvaro T, et al. Medical history and risk of lymphoma: results of a European casecontrol study (EPILYMPH)［J］. J Cancer Res Clin Oncol, 2009, 135(8): 1099-1107. ［28］ Marcucci F, Mele A. Hepatitis viruses and nonHodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities［J］. Blood, 2011, 117(6): 1792-1798. ［29］ Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in nonHodgkin lymphoma: a systematic review and metaanalysis［J］. Intern Med J, 2010, 40(9): 633-641. ［30］ Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of nonHodgkin lymphoma in South Korea: a cohort study［J］. Lancet Oncol, 2010, 11(9): 827-834. ［31］ Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell nonHodgkin′s lymphoma［J］. Ann Hematol, 2008, 87(6): 475-480.

相关文章15

编辑推荐

Metrics

本文评价